Is the era of the scientist-CEO over in Big Pharma? The Financial Times suggests it's so. And to hear the experts tell it, there's a reason for that. Executives with lots of commercial and marketing
New Novartis (NYSE:NVS) chief Joe Jiminez (photo) is talking execution again. In an interview with the Financial Times, Jiminez described some of his initiatives--and they're all about the E word.
Novartis has released more information about its U.S. drug reorganization: Andre Wyss is set to take the reins of that business, which is restructuring and cutting about 20 percent of its
Now that it's done a $39.3 billion deal for Alcon, Novartis is joining the "no-megamerger" pharma fraternity. At the company's annual shareholders' meeting in Basel, Switzerland, new CEO Joe Jiminez
Newly-appointed Novartis CEO Joe Jimenez got his first chance to take the lead role at the annual shareholders' meeting today, and started to give the industry a better feel for just the kind of new
There's nothing like a surprise CEO announcement to get the media excited. Novartis CEO Daniel Vasella's (photo) confession that he'd be handing off his CEO responsibilities to pharma head Joe
Look out, drugmakers: Another executive who spent his formative years outside the industry will take over at a Big Pharma near you. And much to the chagrin of the press, he's replacing one of the
Business gurus often suggest that healthcare import some of the MBA-type approaches--such as "best practices"--that are common in other industries. So is it any surprise that a particular benchmark
Quick, name the top three challenges Big Pharma faces. Generics? Pricing pressure? Tough regulatory environment? If they're not the top three, they're at least significant enough for Daniel
The musical chairs game in Novartis' top management ranks is continuing as new pharma chief Joe Jimenez revamps the ranks. The Swiss drugmaker has appointed Ludwig Hantson to top its U.S.